Molecular Imaging
Highly Engaged Employees
Healthcare Services · Illinois, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
230 E Ogden Ave Ste 100, Hinsdale, Illin...Phone Number
(630) 325-6300Website
www.molecularscans.comRevenue
$10.4 MillionIndustry
About Molecular Imaging
Molecular Imaging Org Chart
Is Molecular Imaging your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Molecular Imaging has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Molecular Imaging has new funding data
Website visits: Recent activity has been detected on your website
Molecular Imaging, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Molecular Imaging
Click to see if Molecular Imaging had a recent Job posting/layoffs
Check out if Molecular Imaging is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Molecular Imaging launches new products
Earning: See what the market has to say on Molecular Imaging recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Molecular Imaging
Compare insights from companies similar to Molecular Imaging, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Molecular Imaging is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Molecular Imaging is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Molecular Imaging.
Molecular Imaging financials insights
Gather financial insights about Molecular Imaging, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Debt
$350K
Debt
$564K
Molecular Imaging Tech Stack
A closer look at the technologies used by Molecular Imaging
Molecular Imaging News & Media
Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting
- ATNM-400 shows; superior prostate cancer cell killing compared to androgen receptor inhibitor Xtandi® (enzalutamide), the ability to overcome Xtandi resistance, and activity in combination - ATNM-400 is more efficacious than both Pluvicto® (177-Lu-PSMA-617) and Ac-225-PSMA-617 targeted...Neurophet to Participate in SNMMI 2025: Showcasing 'Neurophet SCALE PET' and Expanding Global Partnerships
Showcasing brain imaging analysis solutions such as Neurophet SCALE PET, which provides SUVR values for PET tracers Engaging in partnering discussions with global pharma companies and exploring business development opportunities with radiopharmaceutical companies SEOUL, South Korea, June...Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting
NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the presentation of preclinical and translational pharmacokinetics (PK) data of GD2-SADA in a poster at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) Mid-Winter andActinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
- Novel targeted radiotherapy-based combination being studied as potential backbone therapy potential relapsed or refractory acute myeloid leukemia - Actimab-A + CLAG-M produced high rates of response, measurable residual disease negativity, bone marrow transplant access and improved...
Top Healthcare Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Molecular Imaging
Molecular Scans is a healthcare provider based in Chicago that specializes in high-quality imaging exams, including MRI, EMG, and Digital X-Ray. The company is committed to offering competitive pricing and ensuring that their fees are less than or equal to those of comparable facilities. Their team consists of board-certified radiologists and exper... Read More